DiaSorin to Acquire Luminex for ~$1.8B

April 13, 2021 Auto Bot Acquire, M&A, MedTech 0

Shots:

  • DiaSorin to acquire Luminex for $37.00/ share in an all-cash transaction, with 23% premium based on closing stock price of Luminex on 24 Feb, 2021, making a total equity value of $1.8B
  • The acquisition will boost DiaSorin’s presence in the molecular diagnostics space in the US with the addition of Luminex’s molecular diagnostics multiplexing technology and a portfolio
  • Additionally, the acquisition will accelerate Luminex technology and solutions’ penetration outside the US via DiaSorin’s commercial and geographical reach

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Liminex

The post DiaSorin to Acquire Luminex for ~$1.8B first appeared on PharmaShots.